純利益率
2005年以降
計算
Eli Lilly & Co.、純利益率、長期トレンド計算
| 純利益率 | = | 100 | × | 当期純利益(損失)1 | ÷ | 収入1 | |
|---|---|---|---|---|---|---|---|
| 2024/12/31 | 23.51% | = | 100 | × | 10,590,000) | ÷ | 45,042,700) |
| 2023/12/31 | 15.36% | = | 100 | × | 5,240,400) | ÷ | 34,124,100) |
| 2022/12/31 | 21.88% | = | 100 | × | 6,244,800) | ÷ | 28,541,400) |
| 2021/12/31 | 19.71% | = | 100 | × | 5,581,700) | ÷ | 28,318,400) |
| 2020/12/31 | 25.24% | = | 100 | × | 6,193,700) | ÷ | 24,539,800) |
| 2019/12/31 | 37.27% | = | 100 | × | 8,318,400) | ÷ | 22,319,500) |
| 2018/12/31 | 13.16% | = | 100 | × | 3,232,000) | ÷ | 24,555,700) |
| 2017/12/31 | -0.89% | = | 100 | × | (204,100) | ÷ | 22,871,300) |
| 2016/12/31 | 12.90% | = | 100 | × | 2,737,600) | ÷ | 21,222,100) |
| 2015/12/31 | 12.07% | = | 100 | × | 2,408,400) | ÷ | 19,958,700) |
| 2014/12/31 | 12.19% | = | 100 | × | 2,390,500) | ÷ | 19,615,600) |
| 2013/12/31 | 20.27% | = | 100 | × | 4,684,800) | ÷ | 23,113,100) |
| 2012/12/31 | 18.09% | = | 100 | × | 4,088,600) | ÷ | 22,603,400) |
| 2011/12/31 | 17.90% | = | 100 | × | 4,347,700) | ÷ | 24,286,500) |
| 2010/12/31 | 21.97% | = | 100 | × | 5,069,500) | ÷ | 23,076,000) |
| 2009/12/31 | 19.82% | = | 100 | × | 4,328,800) | ÷ | 21,836,000) |
| 2008/12/31 | -10.17% | = | 100 | × | (2,071,900) | ÷ | 20,378,000) |
| 2007/12/31 | 15.85% | = | 100 | × | 2,953,000) | ÷ | 18,633,500) |
| 2006/12/31 | 16.97% | = | 100 | × | 2,662,700) | ÷ | 15,691,000) |
| 2005/12/31 | 13.52% | = | 100 | × | 1,979,600) | ÷ | 14,645,300) |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
1 千米ドル
競合他社との比較
Eli Lilly & Co.、純利益率、長期トレンド、競合他社との比較
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024/12/31 | 23.51% | 7.59% | 12.77% | -18.53% | 16.33% | 1.68% | 15.84% | 26.68% | 12.62% | 31.07% | 14.77% | -4.86% |
| 2023/12/31 | 15.36% | 8.95% | 24.96% | 17.83% | 19.94% | 21.03% | 41.28% | 0.61% | 3.56% | 30.14% | 13.99% | 36.68% |
| 2022/12/31 | 21.88% | 20.39% | 26.42% | 13.71% | 22.91% | 17.02% | 18.90% | 24.49% | 31.01% | 35.64% | 15.47% | 37.20% |
| 2021/12/31 | 19.71% | 20.54% | 24.25% | 15.08% | 21.84% | 23.05% | 22.26% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| 2020/12/31 | 25.24% | 10.08% | 29.97% | -21.20% | 16.36% | 0.51% | 17.82% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| 2019/12/31 | 37.27% | 23.69% | 35.32% | 13.15% | 16.80% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| 2018/12/31 | 13.16% | 17.36% | 37.25% | 21.81% | 13.33% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| 2017/12/31 | -0.89% | 18.82% | 9.08% | 4.85% | 13.60% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| 2016/12/31 | 12.90% | 23.22% | 35.27% | 22.94% | 15.13% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| 2015/12/31 | 12.07% | 22.50% | 33.13% | 9.45% | 16.33% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| 2014/12/31 | 12.19% | 8.89% | 26.69% | 12.62% | 13.05% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| 2013/12/31 | 20.27% | 21.97% | 27.93% | 15.64% | 14.10% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| 2012/12/31 | 18.09% | 28.70% | 26.11% | 11.12% | 13.10% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| 2011/12/31 | 17.90% | — | 24.08% | 17.46% | 13.50% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| 2010/12/31 | 21.97% | — | 31.56% | 15.92% | 13.58% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| 2009/12/31 | 19.82% | — | 32.09% | 56.42% | 10.30% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| 2008/12/31 | -10.17% | — | 28.57% | 25.47% | 10.38% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| 2007/12/31 | 15.85% | — | 22.12% | 11.19% | 12.42% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| 2006/12/31 | 16.97% | — | 21.29% | 8.85% | 11.69% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| 2005/12/31 | 13.52% | — | 30.56% | 15.62% | 11.24% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
Eli Lilly & Co.、純利益率、長期トレンド、産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
| Eli Lilly & Co. | 製薬、バイオテクノロジー、ライフサイエンス | |
|---|---|---|
| 2024/12/31 | 23.51% | 12.30% |
| 2023/12/31 | 15.36% | 17.95% |
| 2022/12/31 | 21.88% | 22.55% |
| 2021/12/31 | 19.71% | 23.38% |
| 2020/12/31 | 25.24% | 14.07% |
| 2019/12/31 | 37.27% | 23.22% |
| 2018/12/31 | 13.16% | 19.82% |
| 2017/12/31 | -0.89% | 13.06% |
| 2016/12/31 | 12.90% | 20.78% |
| 2015/12/31 | 12.07% | 21.17% |
| 2014/12/31 | 12.19% | 21.24% |
| 2013/12/31 | 20.27% | 21.99% |
| 2012/12/31 | 18.09% | 18.53% |
| 2011/12/31 | 17.90% | 15.70% |
| 2010/12/31 | 21.97% | 15.16% |
| 2009/12/31 | 19.82% | 25.73% |
| 2008/12/31 | -10.17% | 18.17% |
| 2007/12/31 | 15.85% | 15.90% |
| 2006/12/31 | 16.97% | 22.24% |
| 2005/12/31 | 13.52% | 18.33% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
業界との比較: 医療
Eli Lilly & Co.、純利益率、長期トレンド、業界との比較: 医療
| Eli Lilly & Co. | 医療 | |
|---|---|---|
| 2024/12/31 | 23.51% | 7.02% |
| 2023/12/31 | 15.36% | 9.24% |
| 2022/12/31 | 21.88% | 11.62% |
| 2021/12/31 | 19.71% | 12.42% |
| 2020/12/31 | 25.24% | 8.45% |
| 2019/12/31 | 37.27% | 11.58% |
| 2018/12/31 | 13.16% | 9.92% |
| 2017/12/31 | -0.89% | 8.05% |
| 2016/12/31 | 12.90% | 10.68% |
| 2015/12/31 | 12.07% | 11.77% |
| 2014/12/31 | 12.19% | 12.15% |
| 2013/12/31 | 20.27% | 12.81% |
| 2012/12/31 | 18.09% | 11.86% |
| 2011/12/31 | 17.90% | 10.50% |
| 2010/12/31 | 21.97% | 10.48% |
| 2009/12/31 | 19.82% | 15.08% |
| 2008/12/31 | -10.17% | 11.35% |
| 2007/12/31 | 15.85% | 11.02% |
| 2006/12/31 | 16.97% | 13.95% |
| 2005/12/31 | 13.52% | 13.38% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).